Compare · ALXN vs AXGT
ALXN vs AXGT
Side-by-side comparison of Alexion Pharmaceuticals, Inc. (ALXN) and Axovant Gene Therapies Ltd. (AXGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALXN and AXGT operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Alexion Pharmaceuticals, Inc.
- Axovant Gene Therapies Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest ALXN
- Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
- SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
Latest AXGT
- Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
- Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
- Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
- Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
- Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
- Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
- Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy
- Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th